updat model result updat guidanc still assum bayer anim
acquisit close revenu forecast slightli lower
market dynam improv margin uncertainti relat bayer acquisit near-
lower revenu estim flat vs guidanc
consensu reduct reflect new near-term
pressur ruminants/swin includ shift away ractopamin growth
addit difficult weather condit australia note impact
near-term headwind african swine fever suppli disrupt inject bovin
product launch gener rumensin line expect
also lower revenu estim
increas revenu forecast reflect expect greater
benefit bayer report strong sale new revenu estim
combin entiti revenu compound-annual-growth-rate vs prior
compound-annual-growth-rate
beat maintain full year ep estim
vs consensu guidanc impli ep estim
prior estim vs consensu reflect top
line pressur discuss margin improv trend remain track upsid
possibl ep estim also unchang assum bayer ah close
newli issu ep estim ep compound-annual-growth-rate
unchang prior compound-annual-growth-rate
pleas see page report import disclosur
signific opportun stabl annual growth visibl anim
market driven global demand protein uptick new companion anim
drug elanco anim health compani decad experi strong
reput veterinari market one stand-alon publicli trade larg
anim health compani elanco offer investor opportun particip
attract market bayer acquisit creat near-term risk integr equiti
overhang bayer ownership look sound strateg deal accret
closur bayer acquisit
sale compound-annual-growth-rate bayer
faster expect
ep compound-annual-growth-rate bayer
greater synergi bayer
emerg signific product
pipelin
greater expect profit
integr challeng bayer
effici improv take longer
less meaning
elanco spun-out septemb public stand-alone compani ipo
lilli retain ownership march elanco fulli spun
lilli elanco anim health busi sinc elanco largest
compani global anim health market sale brand
sale countri
compani data cowen compani
compani data cowen compani estim
 guidanc assum close guidanc mid singl digit combin guidanc assum unspecifi divestitur synergi good sold good sold profit profit profit margin guidanc underli improv continuegross profit margin assum profit elanco profit margin elanco elanco per investor callsynergi elanco synergi oper expens incom guidanc ebitda bayer interest start tie lillypretax assum changenet incom guidanc share equiti rang cash cowen
compani data cowen compani
compani data cowen compani
compani data cowen compani
anim prevent parasiticid vaccin trifexi credelio interceptor other ex assum competit headwind start anim therapeut gallipr onsior other aratana add nocita entyc ex upsid potenti new product bolt-onsfood anim futur protein health poultri ionophor vaccin parasiticid probiotci etc poultri aquacultur ex swine shared/non-shar antibiot parasiticid implant ex target segmenttot enu ex report -- -- -- -- -- -- distribut agreement contact mfg equin productbay enu larg companion anim parasitisid advantag seresto rumin parasiticid anti-infect strong em presenc ex fx total report bayer estim mix companion livestocktot enu growth ex bayer possibl upsid pipelin local currenc ex cowen
compani data cowen compani
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio discount cash flow
competit dynam global potenti regulatori delay reject failur
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
abil transit product mix gener revenu growth success
pipelin continu execut oper improv plan weather/disease/
polit risk busi success independ compani
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock novarti adr roch hold ltd adr secur
cowen compani llc act underwrit announc initi public offer elanco anim health incorpor subsidiari co
cowen compani llc act financi advisor inc connect acquisit roch hold ag announc februari
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
